BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 74 results. LastUpdate Updated on 03/10/2022 [10:57:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Page2/3 nextPage   results/page


USE OF TROPOMYOSIN ALPHA-4 CHAIN AND PLATELET GLYCOPROTEIN IB BETA CHAIN FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

Publication No.: WO2022186486A1 09/09/2022

Applicant:

PEOPLEBIO INC [KR]

KR_20220125640_PA

Absstract of: WO2022186486A1

The present invention relates to a composition and a diagnostic kit for the diagnosis of Alzheimer's disease, and a method for providing information needed for diagnosing Alzheimer's disease by using the composition and the kit. TPM4, GP1BB, or a combination thereof, which are biomarkers in plasma that were newly developed by the inventors of the present invention, is expressed at a low level in the plasma of an Alzheimer's disease patient group as compared to normal individuals, and thus, through measurement of the expression levels of the biomarkers, whether or not a patient has Alzheimer's disease can be accurately diagnosed early.

traducir

PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS

Publication No.: WO2022187670A1 09/09/2022

Applicant:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]

Absstract of: WO2022187670A1

The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-γ agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-γ agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-γ agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

traducir

ASSAYS FOR DETECTING AND QUANTIFYING A BIOMARKER OF PERICYTE INJURY

Publication No.: US2022283185A1 08/09/2022

Applicant:

UNIV SOUTHERN CALIFORNIA [US]

WO_2021041731_A1

Absstract of: US2022283185A1

A highly sensitive immunoassay has been developed and validated. In various embodiments, the assay comprises an immunoassay usable to measure soluble PDGFRβ (sPDGFR-β) in a human biofluid sample such as cerebrospinal fluid (CSF). In various embodiments, elevated sPDGFR-β in a human biofluid sample reflects pericyte and blood-brain barrier (BBB) injury, and is therefore an early biomarker of human cognitive dysfunction, dementia, and/or Alzheimer's disease.

traducir

Novel Diagnostic Marker for Creutzfeldt-Jakob Disease and Alzheimer's Disease

Publication No.: US2022283184A1 08/09/2022

Applicant:

OTTO MARKUS [DE]
OECKL PATRICK [DE]
HALBGEBAUER STEFFEN [DE]

WO_2021028452_A1

Absstract of: US2022283184A1

The present invention relates to method of diagnosis of diseases associated with synaptic degeneration, in particular of Creutzfeldt-Jakob-Disease or Alzheimer's Disease, and to the use of β-synuclein as a biomarker for diagnosing or assessing the status of diseases associated with synaptic degeneration, in particular of Creutzfeldt-Jakob-Disease or Alzheimer's Disease.

traducir

TDP-43 IN DEGENERATIVE DISEASE

Publication No.: US2022283180A1 08/09/2022

Applicant:

UNIV JOHNS HOPKINS [US]

Absstract of: US2022283180A1

Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD).

traducir

TARGETING LIGANDS FOR TAU PATHOLOGY

Publication No.: US2022283187A1 08/09/2022

Applicant:

ALZECA BIOSCIENCES LLC [US]
TEXAS CHILDRENS HOSPITAL [US]

Absstract of: US2022283187A1

Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

traducir

METHOD FOR IDENTIFYING CARBOHYDRATE DRUG-SENSITIVE PATIENT IN PATIENTS HAVING ALZHEIMER'S DISEASE

Publication No.: US2022280541A1 08/09/2022

Applicant:

SHANGHAI GREEN VALLEY PHARMACEUTICAL CO LTD [CN]
SHANGHAI INST MATERIA MEDICA CAS [CN]

BR_112022001706_A2

Absstract of: US2022280541A1

The present invention relates to identification of a carbohydrate drug-sensitive patient in patients having Alzheimer's disease. The present invention provides a method for identifying a carbohydrate drug-sensitive patient in patients having Alzheimer's disease.

traducir

METHODS FOR TREATING RAN PROTEIN-ASSOCIATED NEUROLOGICAL DISEASES

Publication No.: JP2022538926A 06/09/2022

Applicant:

ユニバーシティーオブフロリダリサーチファンデーション,インク.

US_2022267776_PA

Absstract of: WO2021007110A1

Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein- associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.

traducir

NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS

Publication No.: JP2022538834A 06/09/2022

Applicant:

オハイオ・ステイト・イノベーション・ファウンデーション

US_2022244275_A1

Absstract of: WO2021003403A1

As disclosed herein, the skin can dispatch signals to the brain in the form of exosomes, referred to herein as a "skin-brain axis." Therefore, disclosed herein is a method for diagnosing a brain disease, disorder, or injury in a subject that involves isolating exosomes from the subject and assaying the exosomes for the presence of one or more biomarkers of the disease, disorder, or injury. Also disclosed are methods of treating a subject with a brain disease, disorder, or injury that involves engineering the skin of the subject to produce therapeutic exosomes. Also disclosed are methods of collecting skin-produced exosomes and loading them with therapeutic cargo that can treat one or more diseases, disorders, or injuries of the brain. Also disclosed herein is a method to reduce exosomal release from the skin to reducing trafficking to the brain.

traducir

ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF

Publication No.: US2022275037A1 01/09/2022

Applicant:

MO DINGDING [CN]

WO_2021012082_A1

Absstract of: US2022275037A1

The invention discloses a β-amyloid cyclic ribonucleic acid, a polypeptide and an application thereof. The present invention finds that the APP gene can generate a variety of circular RNAs from the AP coding region through reverse splicing, which is named β-amyloid circular ribonucleic acid circAβ. With the help of the newly established circular RNA research method, a variety of peptides produced by circAβ were identified, and such peptides could be further processed to form Aβ, which in turn formed β-amyloid plaques in primary neuronal cultures, reflecting key hallmarks of AD neuropathology. circAβ and its translated proteins represent novel targets in AD therapy.

traducir

COMPOUNDS FOR IMAGING TAU PROTEIN AGGREGATES

Publication No.: IL295000A 01/09/2022

Applicant:

AC IMMUNE SA [CH]
LIFE MOLECULAR IMAGING LTD [GB]

MX_2018016279_A

Absstract of: WO2018015549A1

The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.

traducir

CLSP DERIVATIVE INCAPABLE OF BEING AFFECTED BY CLSP INHIBITING SUBSTANCE, AND CLSP ACTIVITY ENHANCING/PROTECTING AGENT

Publication No.: US2022275038A1 01/09/2022

Applicant:

UNIV TOKYO MEDICAL [JP]

CN_114531877_PA

Absstract of: US2022275038A1

[Problem] Provided is a calmodulin-like skin protein (CLSP) derivative, which has an activity to suppress neuronal cell dysfunction or cell death associated with e.g., Alzheitner's disease stronger than of humanin, and which is insensitive to an inhibitory action by an inhibitor of the activity; a polypeptide which has an action/activity to potentiate or protect the Alzheimer's disease-suppressing activity by CLSP; and the like.[Solution] A derivative (mutant) of calmodulin-like skin protein (CLSP), characterized by including an endogenous humanin-homogenous region (EHR), which is the core of the activity to suppress the neuronal cell dysfunction or neuronal cell death associated with Alzheimer's disease (CLSP activity), and not including a region to which an inhibitor of the CLSP activity binds; a pharmaceutical composition to suppress the neuronal cell dysfunction or neuronal cell death associated with Alzheimer's disease, the composition including the mutant as an active ingredient; and the like.

traducir

METHOD FOR TREATING ALZHEIMER'S DISEASE BY INHIBITING UPTAKE OF AMINO ACIDS BY T CELLS

Publication No.: US2022273598A1 01/09/2022

Applicant:

SHANGHAI GREEN VALLEY PHARMACEUTICAL CO LTD [CN]
SHANGAHI INST OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES [CN]

BR_112022001793_A2

Absstract of: US2022273598A1

Provided is the use of a reagent for inhibiting the uptake of amino acids by naive T cells in the preparation of a drug for treating Alzheimer's disease in a subject.

traducir

DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES

Publication No.: US2022276264A1 01/09/2022

Applicant:

UNIV ARIZONA STATE [US]

US_2020241014_A1

Absstract of: US2022276264A1

Disclosed are diagnostics kits and compositions for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.

traducir

METHODS FOR DIAGNOSIS AND TREATMENT

Publication No.: EP4048814A1 31/08/2022

Applicant:

GMDX CO PTY LTD [AU]

AU_2020370866_A1

Absstract of: WO2021077176A1

This invention relates generally to systems and methods for diagnosing a neurodegenerative disorder in a subject. In particular embodiments, the methods of the disclosure can be used to for the diagnosis of Mild Cognitive Impairment (MCI), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI), Parkinson's Disease (PD), Dementia or Alzheimer's Disease. In other embodiments, the methods involve treatment of a subject diagnosed with such diseases.

traducir

METHODS FOR EVALUATION AND TREATMENT OF ALZHEIMER'S DISEASE AND APPLICATIONS THEREOF

Publication No.: CN114980801A 30/08/2022

Applicant:

亨廷顿医学研究所

JP_2022536523_A

Absstract of: WO2020252206A1

Methods to determine risk of Alzheimer's disease and applications thereof are described. Generally, systems and methods utilize analyte measurements, such as dicarboxylic acid levels, to determine a risk of Alzheimer's disease. Based on Alzheimer disease risk, diagnostics or treatments can be performed.

traducir

BIOMARKERS AND USES THEREOF FOR DIAGNOSING THE SILENT PHASE OF ALZHEIMER'S DISEASE

Publication No.: CN114981452A 30/08/2022

Applicant:

阿根特公司

KR_20220104706_PA

Absstract of: WO2021083977A1

The present invention relates to a molecular signature of the silent phase of Alzheimer's disease; and to methods using the same, for diagnosing a silent stage of Alzheimer's disease in a subject, stratifying a silent phase of Alzheimer's disease in a subject into different grades of the silent phase, prognosticating the progress of a silent phase of Alzheimer's disease in a subject, and determining a personalized course of treatment in a subject affected with a silent phase of Alzheimer's disease. It also relates to a computer system comprising a machine learning algorithm trained for diagnosing a silent phase of Alzheimer's disease in a subject.

traducir

ANTIBODY DIRECTED AGAINST THE APOE AMINO-TERMINAL FRAGMENT OF 12 KDA

Publication No.: JP2022537736A 29/08/2022

Applicant:

バイオアークティックアーベー

US_2022242939_A1

Absstract of: EP3757125A1

The disclosure relates to an antibody or antigen binding portion thereof, which binds to a neo-epitope of a C-terminal fragment of apolipoprotein E, to methods of producing such an antibody or antigen binding portion thereof, and to therapeutic and diagnostic uses thereof.

traducir

METHODS FOR TREATING RAN PROTEIN-ASSOCIATED NEUROLOGICAL DISEASES

Publication No.: US2022267776A1 25/08/2022

Applicant:

UNIV FLORIDA [US]

JP_2022538926_PA

Absstract of: US2022267776A1

Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein-associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.

traducir

Methods For The Treatment Of Neurodegeneration

Publication No.: US2022267413A1 25/08/2022

Applicant:

MOMENTA PHARMACEUTICALS INC [US]

US_2020055921_A1

Absstract of: US2022267413A1

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or a 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

traducir

METHODS OF DETERMINING ALZHEIMER'S DISEASE

Publication No.: WO2022175672A1 25/08/2022

Applicant:

UNIV MANCHESTER [GB]

Absstract of: WO2022175672A1

The invention relates to molecular biomarkers and particular methods for assessing the likelihood of developing Alzheimer's disease, determining Alzheimer's disease and/or monitoring the progression of Alzheimer's disease in a subject.

traducir

MONOCLONAL ANTIBODY AGAINST AMYLOID BETA, AND METHOD FOR MEASURING AMYLOID BETA-RELATED PEPTIDE USING SAID ANTIBODY

Publication No.: US2022268789A1 25/08/2022

Applicant:

SHIMADZU CORP [JP]

CN_114026109_PA

Absstract of: US2022268789A1

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute ofTechnology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

traducir

TAU EPITOPE AND BINDING MOLECULES

Publication No.: US2022265819A1 25/08/2022

Applicant:

GEN2 NEUROSCIENCE LTD [GB]

WO_2021005019_A1

Absstract of: US2022265819A1

The invention relates to isolated synthetic or recombinant peptides comprising an epitope of human tau 2N4R, wherein the tau peptide sequence comprising the epitope is not phosphorylated. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the non-phosphorylated tau epitopes and to such peptides and binding molecules, such as antibodies, for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

traducir

APPLICATION OF TPK AS A TARGET IN ALZHEIMER'S DISEASE

Publication No.: EP4046657A1 24/08/2022

Applicant:

SHANGHAI RAISING PHARMACEUTICAL CO LTD [CN]

CN_114710952_PA

Absstract of: EP4046657A1

Provided is use of thiamine pyrophosphokinase TPK as a target in the treatment of Alzheimer's disease; and AD symptoms due to the inhibited TPK can be prevented by promoting the kinase activity and/or expression level of TPK protein in brain with TPK as a target.

traducir

BLOOD-BASED ASSAY FOR DIAGNOSING AND TREATING BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

Nº publicación: BR112022004326A2 23/08/2022

Applicant:

UNIV WASHINGTON [US]

CN_114761807_PA

Absstract of: WO2021050733A1

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

previousPage Page2/3 nextPage results/page

punteroimgGo back